New drug MTX325 enters first human tests for Parkinson's
NCT ID NCT07630545
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called MTX325 in healthy volunteers and people with mild to moderate Parkinson's disease. The main goals are to check safety, how the body processes the drug, and whether it reaches the brain. If successful, MTX325 might one day slow the progression of Parkinson's.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MTX325
What this could lead to
If this works, MTX325 could become a treatment that slows or stops Parkinson's disease from getting worse.
What could go wrong
This is a very early Phase 1 trial with only 106 people, focused on safety. It may fail to show benefit or have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Parexel
COMPLETEDLondon, United Kingdom
-
Perceptive
COMPLETEDLondon, United Kingdom
-
Royal Liverpool University Hospital
RECRUITINGLiverpool, United Kingdom
Contact
-
Simbec-Orion
COMPLETEDMerthyr Tydfil, United Kingdom
-
University Hospitals Plymouth NHS Trust, Derriford Hospital
RECRUITINGPlymouth, United Kingdom
Contact